Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Neoadjuvant Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

NCT02243358 is registered in ClinicalTrials.gov with Henry Ford Health System as lead sponsor.

NCT NCT02243358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02243358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Neoadjuvant Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Lead sponsor
Henry Ford Health System
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
January 14, 2020
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas neoplasm malignant resectable